Be prepared for a short-term gain that may be a long-term pain. The AmericanMedical Association has claimed a major political victory with passage ofthe Medicare Prescription Drug Improvement and Modernization Act of 2003,and I certainly hope the AMA is correct. Certainly the pay increase overthe next 2 years is great. However, I have concerns about many of the otherissues addressed in the bill.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.